In re Ciprofloxacin Hydrochloride Antitrust Litigation, 544 F.3d 1323, 1328 (Fed. Cir. 2008).
2.
Id..
3.
Id..
4.
Id..
5.
Id. at 1329.
6.
Id..
7.
Id..
8.
Id..
9.
Id..
10.
Id. at 1327.
11.
Id..
12.
Id. at 1336.
13.
Id. at 1340.
14.
Id. at 1332.
15.
Id. at 1331.
16.
Id. at 1332.
17.
Id. at 1333.
18.
Id. at 1331.
19.
Id. at 1333.
20.
Id. at 1334.
21.
Id..
22.
Id. at 1335.
23.
Id. at 1337.
24.
Id..
25.
Id. at 1340.
26.
See generallyShreveG. R.Raven-HansenP. (2002) Understanding Civil Procedure. Newark, NJ, USA: Mathew Bender & Co. pp. 224–225.
27.
Celgene v. KV Pharmaceuticals. No. 07-4819, 2008 WL 2856469, at ∗1 (D.N.J. July 22, 2008).
28.
Id..
29.
See alsoApproved Drug Products with Therapeutic Equivalence Evaluations (the ‘Orange Book ’).
30.
Celgene, 2008 WL 2856469 at ∗1.
31.
Defs. Mem. of Law in Supp. of its Mot. for Sanctions Pursuant to Fed. R. Civ. P. 11 at 2-3, Celgene Corp. v. KV Pharmaceutical Co., No. 07-4819 (D.N.J. July 22, 2008) (Docket Entry No. 46) (hereinafter ‘Defs. Mem.’).
32.
Id. at 3.
33.
Celgene Corp., 2008 WL 2856469 at ∗1.
34.
Celgene Corp. v. KV Pharmaceutical Co., No. 07-4819 (D.N.J. July 22, 2008) (Docket Entry No. 51) (hereinafter ‘Pls.’ Letter').
35.
Celgene Corp., 2008 WL 2856469 at ∗2 (citing Q-Pharma, Inc. v. Andrew Jergens Co., 360 F.3d 1295, 1300 (Fed. Cir. 2004).
36.
Id. at ∗4.
37.
Id. at ∗3.
38.
Id..
39.
Id. at ∗4.
40.
Id. at ∗5.
41.
SB Pharmco Puerto Rico, Inc. v. Mutual Pharmaceutical Co., Inc., 552 F.Supp.2d 500, 503 (E.D. Pa. 2008).
42.
21 U.S.C. 355 (j)(2)(B)(ii).
43.
SB Pharmco, 552 F.Supp.2d at 503.
44.
Id. at 504.
45.
Id..
46.
Id..
47.
Id..
48.
Id..
49.
Id..
50.
SB Pharmco Puerto Rico, Inc., 552 F.Supp.2d 500 at 506.
51.
Id..
52.
Id. at 507.
53.
Id. at 510.
54.
Id. at 514.
55.
Id. at 515.
56.
SB Pharmco Puerto Rico, Inc., 552 F.Supp.2d at 508 (emphasis in original).
